
BI 1467335
CAS No. 1478364-68-9
BI 1467335 ( PXS-4728A | PXS-4728 )
产品货号. M12040 CAS No. 1478364-68-9
BI 1467335 (PXS-4728A, PXS-4728) 是一种有效的、选择性的、口服活性的 SSAO/VAP-1 (AOC3) 抑制剂,IC50 为 5 nM。
纯度: >98% (HPLC)






规格 | 价格/人民币 | 库存 | 数量 |
2MG | ¥502 | 有现货 |
![]() ![]() |
5MG | ¥786 | 有现货 |
![]() ![]() |
10MG | ¥1320 | 有现货 |
![]() ![]() |
25MG | ¥2811 | 有现货 |
![]() ![]() |
50MG | ¥4496 | 有现货 |
![]() ![]() |
100MG | 获取报价 | 有现货 |
![]() ![]() |
200MG | 获取报价 | 有现货 |
![]() ![]() |
500MG | 获取报价 | 有现货 |
![]() ![]() |
1G | 获取报价 | 有现货 |
![]() ![]() |
生物学信息
-
产品名称BI 1467335
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述BI 1467335 (PXS-4728A, PXS-4728) 是一种有效的、选择性的、口服活性的 SSAO/VAP-1 (AOC3) 抑制剂,IC50 为 5 nM。
-
产品描述BI 1467335 (PXS-4728A,?PXS-4728) is a potent, selective, orally active SSAO/VAP-1 (AOC3) inhibitor with IC50 of 5 nM; displays >500-fold selective for VAP-1/SSAO over all the related human amine oxidases; diminishes leukocyte rolling and adherence induced by CXCL1/KC, also inhibits the migration of neutrophils to the lungs in response to LPS, Klebsiella pneumoniae lung infection and CLP induced sepsis.Steatohepatitis,Phase 2 Clinical.
-
体外实验——
-
体内实验——
-
同义词PXS-4728A | PXS-4728
-
通路Others
-
靶点Other Targets
-
受体Other Targets
-
研究领域Other Indications
-
适应症Steatohepatitis
化学信息
-
CAS Number1478364-68-9
-
分子量316.8
-
分子式C15H21FN2O2.HCl
-
纯度>98% (HPLC)
-
溶解度In Vitro:?DMSO : 250 mg/mL (789.14 mM)
-
SMILESCC(C)(C)NC(=O)C1=CC=C(C=C1)OCC(=CF)CN.Cl
-
化学全称(E)-4-((2-(aminomethyl)-3-fluoroallyl)oxy)-N-(tert-butyl)benzamide hydrochloride
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1. Schilter HC, et al. Respir Res. 2015 Mar 20;16:42.
2. Jarnicki AG, et al. Br J Pharmacol. 2016 Nov;173(22):3161-3175.
3. Katagiri D, et al. Respir Res. 2015 Mar 20;16:42.
产品手册




关联产品
-
M-2420
M-2420 is a fluorogenic substrate containing β-secretase site of the Swedish mutation of amyloid precursor protein (APP).
-
Sodium Glucoheptonat...
葡庚糖酸钠用作肾脏和脑显像剂 Tc-99m 放射性标记的试剂盒,可用于脑肿瘤检测。
-
V2 receptor (V2R) a...
c(Bua-Cpa-Thi-Val-Asn-Cys)-Pro-d-Arg-NEt2 acetate is a potent, selective and short-acting peptidic V2 receptor (V2R) agonist with EC50s of 0.07 and 0.02 nM for hV2R and rV2R, respectively.